# Active Surveillance After Neoadjuvant Adebrelimab Combined With Chemoradiotherapy for Resectable ESCC

> **NCT06861894** · PHASE2 · NOT_YET_RECRUITING · sponsor: **Zhigang Li** · enrollment: 164 (estimated)

## Conditions studied

- Esophageal Squamous Cell Carcinoma

## Interventions

- **DRUG:** Adebrelimab and nab-paclitaxel and carboplatin
- **RADIATION:** Radiation
- **PROCEDURE:** standard oesophagectomy
- **OTHER:** active surveillance

## Key facts

- **NCT ID:** NCT06861894
- **Lead sponsor:** Zhigang Li
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2025-07
- **Primary completion:** 2027-03
- **Final completion:** 2029-03
- **Target enrollment:** 164 (ESTIMATED)
- **Last updated:** 2025-05-15


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06861894

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06861894, "Active Surveillance After Neoadjuvant Adebrelimab Combined With Chemoradiotherapy for Resectable ESCC". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT06861894. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*